STOCK TITAN

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares. The sales were made solely to cover tax and social security obligations from a legacy Virtual Stock Option Plan (Prior VSOP), which granted virtual options to key members of management. The tax obligations arose as a result of option exercises pursuant to the terms of the Prior VSOP.

Except for tax obligations, all three members of the management team do not plan to sell additional shares in the foreseeable future.

About CureVac

CureVac (Nasdaq:CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac SE has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.

CureVac Investor Relations Contact

Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

CureVac Media Contact

Bettina Jödicke-Braas, Manager Communications
CureVac, Tübingen, Germany
T: 49 7071 9883-1087
bettina.joedicke-braas@curevac.com

Forward-Looking Statements CureVac

This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

SOURCE: CureVac



View source version on accesswire.com:
https://www.accesswire.com/731921/CureVac-Members-of-Management-Sell-Shares-to-Cover-Tax-Obligations-from-Long-Term-Incentive-Program

CureVac N.V.

NASDAQ:CVAC

CVAC Rankings

CVAC Latest News

CVAC Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Health Technology, Pharmaceuticals: Major
Germany
Tuebingen

About CVAC

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o